Form 4: PMV Pharmaceuticals Director Receives Stock Option Grant

Director Kirsten Flowers was granted 42,000 stock options in PMV Pharmaceuticals, Inc. as part of an equity incentive.

Summary

• Director Kirsten Flowers acquired 42,000 stock options in PMV Pharmaceuticals, Inc. (PMVP).
• The options have an exercise price of $1.19 per share.
• The grant date for the transaction was June 4, 2026.
• The options are scheduled to expire on June 4, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which is neutral in nature.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The issuance of stock options results in potential future dilution for existing shareholders.

Risks

• Market volatility affecting the value of the underlying common stock.
• The exercise price of $1.19 may be subject to market fluctuations relative to the future trading price of PMVP.

Future Outlook

The options vest on the earlier of June 4, 2027, or the date of the Issuer's next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board members maintain a vested interest in company performance.

Comparison to Industry Standards

• The use of time-based vesting (one year or next annual meeting) is consistent with standard industry practices for director compensation in small-cap biotech firms.

Stakeholder Impact

• Minor potential dilution for existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 4, 2027, or the date of the next annual meeting.

Key Dates

Keywords

PMVP, PMV Pharmaceuticals, Form 4, Director Compensation, Stock Options, Insider Trading